Description: MF-766 is a highly potent, selective, and orally active EP4 antagonist with a Ki of 0.23 nM, acting as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. It is useful for cancer and inflammation diseases research [1][2]. Target: Prostaglandin...

MF766 is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 (Ki = 0.23 nM). It is selective for EP4 over the PGD2 receptor subtype DP1 (Ki = 1,648 nM) as well as the EP1, EP2, EP3, and CRTH2/DP2 receptors, the PGI2 receptor (IP), thromboxane receptor (TP), and PGF receptor (FP, Kis = >6,000 nM for...